Table 1 Clinical characteristics of the study population
Subgroup | HI | SLE | Neuropsychiatric SLE according to: | |||
|---|---|---|---|---|---|---|
ACR | SLICC B | SLICC A | ||||
Number (n) | 25 | 70 | 42 | 21 | 15 | |
Age [years], median (range) | 37.2 (23–52) | 36.0 (18–51) | 36.9 (18–49) | 36.9 (23–48) | 39.2 (23–48) | |
Education level1 | 1 | NA | 1.4% | 4.7% | 4.7% | 0% |
2 | 47.1% | 61.9% | 61.9% | 60% | ||
3 | 50% | 33.3% | 33.3% | 40% | ||
MADRS-S scores (mean ± SD)2 | 2.4 ± 1.6 | 12.4 ± 0.9 | 15.8 ± 1.1 | 15.3 ± 1.7 | 16.5 ± 2.0 | |
Disease duration [years] (mean ± SD) |  | 11.0 ± 6.4 | 11.6 ± 10.6 | 10.6 ± 2.1 | 11.5 ± 5.7 | |
SDI score (mean ± SD)3 |  | 0.7 ± 1.4 | 0.8 ± 1.4 | 1.1 ± 0.7 | 1.3 ± 0.7 | |
SLEDAI-2 K score (mean ± SD)4 |  | 2.4 ± 8.5 | 2.6 ± 0.7 | 2.7 ± 0.0 | 3.0 ± 0.7 | |
Anti-nuclear antibody % | Â | 98.5% | 97.6% | 100% | 100% | |
Anti-double stranded DNA % | Â | 58.5% | 64.2% | 71.4% | 66.6% | |
Anti-Smith antibody % | Â | 12.8% | 9.5% | 4.7%% | 0% | |
Anti-phospholipid antibody % | Â | 32.8% | 38.0% | 42.8% | 46.6% | |
Corticosteroid treatment % | Â | 78.6% | 83.3% | 80.9% | 80.0% | |
Corticosteroid daily dose (mg/day), median (range) |  | 5 (0–25) | 5 (0–25) | 5 (0–15) | 5 (0–15) | |
DMARD treatment % | Non-antimalarial | Â | 60.0% | 57.1% | 47.6% | 46.6% |
Antimalarial | Â | 78.6% | 73.8% | 80.9% | 80.0% | |